OBJECTIVE: To evaluate the efficiency of mitoxantrone in multiple sclerosis. METHODS:
Forty two patients with confirmed multiple sclerosis, selected as having a very active disease …

A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49
patients with relapsing, secondary multiple sclerosis. Patients were randomized to receive …

We designed a randomized, placebo-controlled, multicentre trial involving 51 relapsing-
remitting multiple sclerosis patients to determine the clinical efficacy of mitoxantrone …

BACKGROUND:: Mitoxantrone, an intravenously administered immunosuppressant that
inhibits T-cell, B-cell, and macrophage proliferation, is indicated for reducing neurologic …

Background: Mitoxantrone was approved by the French health authority (AFSAPPS) in
October 2003 to treat patients with aggressive multiple sclerosis (MS). Objective: To report …

Mitoxantrone (Novantrone®), a synthetic anthracenedione derivative, is an antineoplastic,
immunomodulatory agent. Its presumed mechanism of action in patients with multiple …

Objective: To evaluate the effects of mitoxantrone (Mx) in progressive multiple sclerosis (MS)
on MRI. Methods: A total of 194 patients with worsening relapsing-remitting or secondary …

Background Treatment options for patients with secondary progressive multiple sclerosis are
few. Encouraging results in open-label studies prompted this randomised trial of …

A randomised double-blind, placebo-controlled trial of high-dose, pulsed intravenous
methylprednisolone was carried out in 50 individuals with multiple sclerosis; 22 patients …

We treated 13 patients with progressive MS with mitoxantrone. All patients received a
standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with …